Prolonged increase in rat hippocampal chemokine signalling after status epilepticus

Journal of Neuroimmunology

Volumn 245, Issue 1-2, 2012, Pages 15-22

  Kan, Anne A ^a   van der Hel, W Saskia ^b   Kolk, Sharon M ^c   Bos, Ineke W M ^a   Verlinde, Suzanne A M W ^b   van Nieuwenhuizen, Onno ^b   de Graan, Pierre N E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY   (Netherlands)

Author keywords

CCL4; CCR5; Chemokines; Epileptogenesis; Temporal lobe epilepsy

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL POPULATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; EPILEPTIC STATE; EPILEPTOGENESIS; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION; TEMPORAL LOBE EPILEPSY; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CHEMOKINE CCL4; DISEASE MODELS, ANIMAL; EPILEPSY, TEMPORAL LOBE; HIPPOCAMPUS; MALE; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, CCR5; SIGNAL TRANSDUCTION; STATUS EPILEPTICUS; UP-REGULATION;

EID: 84859649848     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.01.012     Document Type: Article

References (61)

1. Allen N.J., Attwell D. A chemokine-glutamate connection. Nat. Neurosci. 2001, 4(7):676-678.
2. Bajetto A., Bonavia R., Barbero S., Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J. Neurochem. 2002, 82(6):1311-1329.
3. Biber K., Zuurman M.W., Dijkstra I.M., Boddeke H.W. Chemokines in the brain: neuroimmunology and beyond. Curr. Opin. Pharmacol. 2002, 2(1):63-68.
4. Biber K., de Jong E.K., van Weering H.R., Boddeke H.W. Chemokines and their receptors in central nervous system disease. Curr. Drug Targets 2006, 7(1):29-46.
5. Buchhalter J. Status epilepticus presenting as new-onset seizures in children. Epilepsy Curr. 2011, 11(4):112-113.
6. Cascino G.D. When drugs and surgery don't work. Epilepsia 2008, 49(Suppl. 9):79-84.
7. Fabene P.F., Navarro M.G., Martinello M., Rossi B., Merigo F., Ottoboni L., Bach S., Angiari S., Benati D., Chakir A., Zanetti L., Schio F., Osculati A., Marzola P., Nicolato E., Homeister J.W., Xia L., Lowe J.B., McEver R.P., Osculati F., Sbarbati A., Butcher E.C., Constantin G. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med. 2008, 14(12):1377-1383.
8. Fabene P.F., Bramanti P., Constantin G. The emerging role for chemokines in epilepsy. J. Neuroimmunol. 2010, 224(1-2):22-27.
9. Foresti M.L., Arisi G.M., Katki K., Montanez A., Sanchez R.M., Shapiro L.A. Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus. J. Neuroinflammation 2009, 6:40.
10. Friedman A., Kaufer D., Heinemann U. Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. Epilepsy Res. 2009, 85(2-3):142-149.
11. Galasso J.M., Harrison J.K., Silverstein F.S. Excitotoxic brain injury stimulates expression of the chemokine receptor CCR5 in neonatal rats. Am. J. Pathol. 1998, 153(5):1631-1640.
12. Gorter J.A., van Vliet E.A., Aronica E., Breit T., Rauwerda H., Lopes da Silva F.H., Wadman W.J. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J. Neurosci. 2006, 26(43):11083-11110.
13. Guan E., Wang J., Roderiquez G., Norcross M.A. Natural truncation of the chemokine MIP-1 beta /CCL4 affects receptor specificity but not anti-HIV-1 activity. J. Biol. Chem. 2002, 277(35):32348-32352.
14. Guzik-Kornacka A., Sliwa A., Plucinska G., Lukasiuk K. Status epilepticus evokes prolonged increase in the expression of CCL3 and CCL4 mRNA and protein in the rat brain. Acta Neurobiol. Exp. (Wars) 2011, 71(2):193-207.
15. Hauser W.A., Annegers J.F., Kurland L.T. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991, 32(4):429-445.
16. Kadowaki T., Nakadate K., Sakakibara S., Hirata K., Ueda S. Expression of Iba1 protein in microglial cells of zitter mutant rat. Neurosci. Lett. 2007, 411(1):26-31.
17. Kuijpers M., van Gassen K.L., de Graan P.N., Gruol D. Chronic exposure to the chemokine CCL3 enhances neuronal network activity in rat hippocampal cultures. J. Neuroimmunol. 2010, 229(1-2):73-80.
18. Kwan P., Brodie M.J. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003, 60(11 Suppl. 4):S2-S12.
19. Ladeby R., Wirenfeldt M., Garcia-Ovejero D., Fenger C., Dissing-Olesen L., Dalmau I., Finsen B. Microglial cell population dynamics in the injured adult central nervous system. Brain Res. Brain Res. Rev. 2005, 48(2):196-206.
20. Lee T.S., Mane S., Eid T., Zhao H., Lin A., Guan Z., Kim J.H., Schweitzer J., King-Stevens D., Weber P., Spencer S.S., Spencer D.D., de Lanerolle N.C. Gene expression in temporal lobe epilepsy is consistent with increased release of glutamate by astrocytes. Mol. Med. 2007, 13(1-2):1-13.
21. Lenz J.C., Rockstroh J.K. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges. Expert Opin. Drug Metab. Toxicol. 2010, 6(9):1139-1150.
22. Leroy C., Pierre K., Simpson I.A., Pellerin L., Vannucci S.J., Nehlig A. Temporal changes in mRNA expression of the brain nutrient transporters in the lithium-pilocarpine model of epilepsy in the immature and adult rat. Neurobiol. Dis. 2011, 43(3):588-597.
23. Liimatainen S., Fallah M., Kharazmi E., Peltola M., Peltola J. Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy. J. Neurol. 2009, 256(5):796-802.
24. Liu J.X., Cao X., Tang Y.C., Liu Y., Tang F.R. CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus. J. Neurochem. 2007, 100(4):1072-1088.
25. Loscher W., Schmidt D. New horizons in the development of antiepileptic drugs: innovative strategies. Epilepsy Res. 2006, 69(3):183-272.
26. Louboutin J.P., Chekmasova A., Marusich E., Agrawal L., Strayer D.S. Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage. FASEB J. 2011, 25(2):737-753.
27. Manley N.C., Bertrand A.A., Kinney K.S., Hing T.C., Sapolsky R.M. Characterization of monocyte chemoattractant protein-1 expression following a kainate model of status epilepticus. Brain Res. 2007, 1182:138-143.
28. Mathern G.W., Babb T.L., Vickrey B.G., Melendez M., Pretorius J.K. The clinical-pathogenic mechanisms of hippocampal neuron loss and surgical outcomes in temporal lobe epilepsy. Brain 1995, 118(Pt 1):105-118.
29. Mennicken F., Chabot J.G., Quirion R. Systemic administration of kainic acid in adult rat stimulates expression of the chemokine receptor CCR5 in the forebrain. Glia 2002, 37(2):124-138.
30. Murdoch C., Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000, 95(10):3032-3043.
31. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., Power C.A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52(1):145-176.
32. Oby E., Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006, 47(11):1761-1774.
33. Parpura V., Basarsky T.A., Liu F., Jeftinija K., Jeftinija S., Haydon P.G. Glutamate-mediated astrocyte-neuron signalling. Nature 1994, 369(6483):744-747.
34. Peltola J., Palmio J., Korhonen L., Suhonen J., Miettinen A., Hurme M., Lindholm D., Keranen T. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res. 2000, 41(3):205-211.
35. Pitkanen A., Sutula T.P. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol. 2002, 1(3):173-181.
36. Quandt J., Dorovini-Zis K. The beta chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J. Neuropathol. Exp. Neurol. 2004, 63(4):350-362.
37. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32(3):281-294.
38. Ransohoff R.M. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 2009, 31(5):711-721.
39. Ravizza T., Rizzi M., Perego C., Richichi C., Veliskova J., Moshe S.L., De Simoni M.G., Vezzani A. Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. Epilepsia 2005, 46(Suppl. 5):113-117.
40. Ravizza T., Gagliardi B., Noe F., Boer K., Aronica E., Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol. Dis. 2007, 29(1):142-160.
41. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav. Immun. 2003, 17(1):13-19.
42. Roch C., Leroy C., Nehlig A., Namer I.J. Predictive value of cortical injury for the development of temporal lobe epilepsy in 21-day-old rats: an MRI approach using the lithium-pilocarpine model. Epilepsia 2002, 43(10):1129-1136.
43. Sankar R., Shin D.H., Liu H., Mazarati A., Pereira de Vasconcelos A., Wasterlain C.G. Patterns of status epilepticus-induced neuronal injury during development and long-term consequences. J. Neurosci. 1998, 18(20):8382-8393.
44. Sayana S., Khanlou H. Maraviroc: a new CCR5 antagonist. Expert Rev. Anti Infect. Ther. 2009, 7(1):9-19.
45. Schwarcz R. Early glial dysfunction in epilepsy. Epilepsia 2008, 49(Suppl. 2):1-2.
46. Seifert G., Carmignoto G., Steinhauser C. Astrocyte dysfunction in epilepsy. Brain Res. Rev. 2010, 63(1-2):212-221.
47. Shukaliak J.A., Dorovini-Zis K. Expression of the beta-chemokines RANTES and MIP-1 beta by human brain microvessel endothelial cells in primary culture. J. Neuropathol. Exp. Neurol. 2000, 59(5):339-352.
48. Sloviter R.S. Hippocampal epileptogenesis in animal models of mesial temporal lobe epilepsy with hippocampal sclerosis: the importance of the "latent period" and other concepts. Epilepsia 2008, 49(Suppl. 9):85-92.
49. Stafstrom C.E. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr. Opin. Neurol. 2010, 23(2):157-163.
50. Taub D.D., Conlon K., Lloyd A.R., Oppenheim J.J., Kelvin D.J. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 1993, 260(5106):355-358.
51. Temkin N.R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001, 42(4):515-524.
52. Tran P.B., Miller R.J. Chemokine receptors: signposts to brain development and disease. Nat. Rev. Neurosci. 2003, 4(6):444-455.
53. van der Hel W.S., Notenboom R.G., Bos I.W., van Rijen P.C., van Veelen C.W., de Graan P.N. Reduced glutamine synthetase in hippocampal areas with neuron loss in temporal lobe epilepsy. Neurology 2005, 64(2):326-333.
54. van Gassen K.L., Netzeband J.G., de Graan P.N., Gruol D.L. The chemokine CCL2 modulates Ca2+ dynamics and electrophysiological properties of cultured cerebellar Purkinje neurons. Eur. J. Neurosci. 2005, 21(11):2949-2957.
55. van Gassen K.L., de Wit M., Koerkamp M.J., Rensen M.G., van Rijen P.C., Holstege F.C., Lindhout D., de Graan P.N. Possible role of the innate immunity in temporal lobe epilepsy. Epilepsia 2008, 49(6):1055-1065.
56. van Vliet E.A., da Costa A.S., Redeker S., van Schaik R., Aronica E., Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130(Pt 2):521-534.
57. Vezzani A. Inflammation and epilepsy. Epilepsy Curr. 2005, 5(1):1-6.
58. Vezzani A., Baram T.Z. New roles for interleukin-1 Beta in the mechanisms of epilepsy. Epilepsy Curr. 2007, 7(2):45-50.
59. Vezzani A., Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005, 46(11):1724-1743.
60. Vezzani A., French J., Bartfai T., Baram T.Z. The role of inflammation in epilepsy. Nat. Rev. Neurol. 2011, 7(1):31-40.
61. Wu Y., Wang X., Mo X., Xi Z., Xiao F., Li J., Zhu X., Luan G., Wang Y., Li Y., Zhang J. Expression of monocyte chemoattractant protein-1 in brain tissue of patients with intractable epilepsy. Clin. Neuropathol. 2008, 27(2):55-63.